Lawan A I, Ogunbiyi J O
Department of Histopathology, Federal Teaching Hospital/Gombe State University, PMB 0037, Gombe, Gombe State, Nigeria.
Department of Pathology, University College Hospital, Ibadan,Nigeria.
West Afr J Med. 2020 Apr-Jun;37(2):100-105.
Colorectal carcinoma is the third most common cancer worldwide. With the push towards targeted therapy in the management of metastatic colorectal carcinoma using anti-EGFR monoclonal antibody, this study aimed to determine the rate of Epidermal Growth Factor Receptor (EGFR) expression in Colorectal Carcinoma, compare the clinicopathological features with the EGFR status and determine if EGFR expression in colorectal carcinoma is of any prognostic significance.
The clinical and demographic data of 54 patients who had colectomy specimens sent to the Pathology Department at the UCH, Ibadan were reviewed to confirm the diagnosis, tumour grade and other clinico-pathological parameters. EGFR expression was assessed on the archival Formalin Fixed Paraffin Embedded (FFPE) blocks using immunohistochemical staining technique. Pearson's chi square test was used to correlate the EGFR status and the clinicopathological features of the tumour.
Epidermal Growth Factor Receptor was expressed in 85.2% of colorectal carcinoma cases. There was an association between EGFR status, depth of tumour invasion and tumour size having P value of 0.05 and 0.043 respectively but there was no association with other clinicopathological parameters. There was no correlation between intensity of staining, percentage of tumour stained and clinicopathological parameters.
This study demonstrates that most cases of colorectal carcinoma diagnosed in the University College Hospital, Ibadan, in the study period showed expression for EGFR. We found that there was an association between depth tumour invasion and tumour size with EGFR expression, suggesting that most EGFR positive colorectal carcinomas are large and show deeper invasion by the tumours. Thus, EGFR positive tumours most likely have poor prognosis.
结直肠癌是全球第三大常见癌症。随着在转移性结直肠癌治疗中采用抗表皮生长因子受体（EGFR）单克隆抗体进行靶向治疗的趋势，本研究旨在确定结直肠癌中表皮生长因子受体（EGFR）的表达率，将临床病理特征与EGFR状态进行比较，并确定结直肠癌中EGFR表达是否具有任何预后意义。
回顾了54例将结肠切除术标本送至伊巴丹大学医院UCH病理科的患者的临床和人口统计学数据，以确认诊断、肿瘤分级和其他临床病理参数。使用免疫组织化学染色技术在存档的福尔马林固定石蜡包埋（FFPE）块上评估EGFR表达。采用Pearson卡方检验来关联EGFR状态与肿瘤的临床病理特征。
85.2%的结直肠癌病例中表达了表皮生长因子受体。EGFR状态与肿瘤浸润深度和肿瘤大小之间存在关联，P值分别为0.05和0.043，但与其他临床病理参数无关联。染色强度、肿瘤染色百分比与临床病理参数之间无相关性。
本研究表明，在研究期间于伊巴丹大学医院UCH诊断的大多数结直肠癌病例显示EGFR表达。我们发现肿瘤浸润深度和肿瘤大小与EGFR表达之间存在关联，这表明大多数EGFR阳性结直肠癌体积较大且肿瘤浸润更深。因此，EGFR阳性肿瘤很可能预后不良。
